Back to today’s briefing

Story perspectives

Pfizer's 30% EPS Surge Amid Medicare Losses; Broadcom Soars 35.7%

8/14/2025

39 5

Summary

Story summary

Zacks.com highlighted Pfizer, Novo Nordisk, and Eli Lilly on August 12, 2025.
Pfizer's Q2 2025 adjusted EPS increased by 30% year-over-year, despite a $1 billion revenue loss from Medicare changes.
The company anticipates continued growth in oncology and plans for major cost savings by 2027.
Broadcom's shares surged 35.7% this year, fueled by demand for AI semiconductors.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 reshaped pharmaceutical revenue, causing Pfizer to face a $1 billion revenue loss. By Q2 2025, Pfizer reported a 30% increase in adjusted EPS, reflecting the industry's adaptation to regulatory changes. This trend highlights the intersection of healthcare and technology, as seen in Broadcom's 35.7% share surge driven by AI semiconductor demand.

1 of 2

Story summary

Zacks.com highlighted Pfizer, Novo Nordisk, and Eli Lilly on August 12, 2025.
Pfizer's Q2 2025 adjusted EPS increased by 30% year-over-year, despite a $1 billion revenue loss from Medicare changes.
The company anticipates continued growth in oncology and plans for major cost savings by 2027.
Broadcom's shares surged 35.7% this year, fueled by demand for AI semiconductors.

1 / 2